临床药师参与布鲁菌感染性心内膜炎1例治疗实践及分析

doi:10.19803/j.1672-8629.2020.12.18

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (12): 930-933.
DOI: 10.19803/j.1672-8629.2020.12.18

临床药师参与布鲁菌感染性心内膜炎1例治疗实践及分析

余雄杰, 张静, 李园, 王鹏, 黄年旭, 陈锦华^*

武汉亚洲心脏病医院,湖北武汉 430022

收稿日期:2019-10-21 修回日期:2020-12-07 出版日期:2020-12-15 发布日期:2020-12-07
通讯作者: ^*陈锦华,女,本科,主任药师,医院药学与药事管理。E-mail:2694691756@qq.com
作者简介:余雄杰,男,硕士,副主任药师,临床药物治疗与合理用药。
基金资助:
武汉市卫生计生委科研项目(WX18D35):PDCA循环管理法对降低抗菌药物使用强度的干预研究

One Case of Participation of Clinical Pharmacists in Treatment of Brucella Endocarditis

YU Xiongjie, ZHANG Jing, LI Yuan, WANG Peng, HUANG Nianxu, CHEN Jinhua^*

Wuhan Asia Heart Hospital,Wuhan Hubei 430022,China

Received:2019-10-21 Revised:2020-12-07 Online:2020-12-15 Published:2020-12-07

摘要/Abstract

摘要： 目的探讨临床药师在布鲁菌感染性心内膜炎患者治疗中的作用。方法临床药师依靠药学专业知识,参与抗感染治疗、药品不良反应处置及抗凝治疗等过程,协助医师制定优化的药物治疗方案。结果医师采纳临床药师建议,患者病情得到有效控制。结论临床药师参与临床药物治疗实践,可以更好地促进临床合理用药,保障患者用药安全。

关键词: 布鲁菌病, 心内膜炎, 临床药师, 药学监护

Abstract: Objective To investigate the role of clinical pharmacists in the treatment of infective endocarditis with brucella.Methods Clinical pharmacists, using their pharmaceutical expertise, participated in the process of anti-infection treatment, adverse reaction disposal and anticoagulant treatment of one patient while assisting physicians in formulating optimal drug treatment programs.Results The clinicians took the advice of clinical pharmacists, and the patients' condition was effectively controlled.Conclusion The participation of clinical pharmacists in clinical drug therapy can better promote rational clinical drug use and ensure the safety of drug use for patients.

Key words: brucellosis, endocarditis, clinical pharmacist, pharmaceutical care

中图分类号:

R969.3

余雄杰, 张静, 李园, 王鹏, 黄年旭, 陈锦华. 临床药师参与布鲁菌感染性心内膜炎1例治疗实践及分析[J]. 中国药物警戒, 2020, 17(12): 930-933.

YU Xiongjie, ZHANG Jing, LI Yuan, WANG Peng, HUANG Nianxu, CHEN Jinhua. One Case of Participation of Clinical Pharmacists in Treatment of Brucella Endocarditis[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 930-933.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.2020.12.18

https://www.zgywjj.com/CN/Y2020/V17/I12/930

参考文献

[1] Chen HZ,Lin GW,Wang JY.Practice of Internal Medicine(实用内科学)[M].14th Ed.Beijing:People's Medical Publishing House,2013:529-532.
[2] Ministry of Health,PRC.Brucellosis Diagnosis and Treatment Guide (trial)[J].Information on infectious diseases(传染病信息),2012,25(6):323-324.
[3] Zhang W,BAI CY,ZHOU Q,et al.Analysis of blood culture characteristics of 4 cases of Brucella infection[J].Guangdong Medical Science(广东医学),2011,32(5):644-645.
[4] Reguera JM,Alarcon A,Miralles F,et al.Brucella endocarditis:clinical,diagnostic,and therapeutic approach[J].Eur J Clin Mierobiol Infect Dis,2003,22(11):647-650.
[5] Fan HW.The Sanford Guide to Antimicrobial Therapy (桑德福抗微生物治疗指南) [M].New Translation,48th edition.Beijing:Peking Union Medical College Press,2019:62.
[6] Ma XJ,Yang WJ.Anti-infective therapy and progress of infective endocarditis[J].Chinese Journal of Infection and Chemotherapy(中国感染与化疗杂志),2017,17(6):713-718.
[7] Chinese Society of Cardiovascular Medicine.Expert consensus on the prevention,diagnosis and treatment of infective endocarditis in adults[J].Chinese Journal of Cardiovascular Diseases(中华心血管病杂志),2014,42(10):806-816.
[8] Fan HW.The Sanford Guide to Antimicrobial Therapy (桑德福抗微生物治疗指南) [M].New Translation,48th edition.Beijing:Peking Union Medical College Press,2019:28.
[9] Dohmen PM,Guleri A,Capone A,et al.Daptomycin for the treatment of infective endocarditis:results from a European registry[J].J Antimicrob Chemother,2013,68(4):936-942.
[10] Uleri A,Utili R,Dohmen P,et al.Daptomycin for the treatment of infective endocarditis:results from European Cubicin,Outcomes Registry and Experience ( EU-CORE)[J].Infect Dis Ther,2015,4(3):283-296.
[11] Zou Q,Bu YL,Teng HS.Review of the literature on doxycycline adverse reactions[J].Chinese Journal of Drug Abuse Prevention(中国药物滥用防治杂志),2016,22(6):366-367.
[12] Shi W,Gu M,Ma SP.Literature analysis on the distribution characteristics of primary anti-tuberculosis drug adverse reactions[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(7):434-436.
[13] Liu M,Li ZD.A case study on the scoring method of drug-induced SJS or TEN -Naranjo score and ALDEN score[J].Chinese Journal of Drug Application and Surveillance(中国药物应用与监测杂志),2014,11(4):247-249.

[1]	林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.
[2]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[3]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[4]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.
[5]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[6]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[7]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[8]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[9]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[10]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[11]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[12]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[13]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[14]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[15]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.

临床药师参与布鲁菌感染性心内膜炎1例治疗实践及分析

One Case of Participation of Clinical Pharmacists in Treatment of Brucella Endocarditis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics